Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,816.89
(
-0.11%
)
US TECH 100
24,499.60
(
0.38%
)
Dow Jones
47,916.57
(
-0.56%
)
Brent Oil
92.41
(
0.00%
)
Bitcoin
71,731.99
(
-1.84%
)
News Focus
News Focus
Post# of 257391
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (5) Keep Next 10 Report Keyboard Shortcuts
Replies (5) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122862
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: GD post# 216587

Tuesday, 02/20/2018 6:30:10 PM

Tuesday, February 20, 2018 6:30:10 PM

Post# of 257391
PTLA—(-10%/AH)—CHMP likely to reject Bextrixaban MAA:

https://finance.yahoo.com/news/portola-pharmaceuticals-announces-results-chmp-214747588.html

As a consolation prize, the CHMP will probably approve Andexanet Alfa (the FXa antidote).

As I've presviously posted on multiple occasions, PTLA was lucky to get FDA approval of Bevyxxa (the US brand name for betrixaban) based on a single phase-3 trial with a not-so-impressive p-value. The CHMP is quite reasonable to say no, IMO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (5) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (5) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today